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MaOBJECTIVES This study aimed to investigate the characteristics of neoatherosclerosis (NA) in patients with diabetes
mellitus (DM) after drug-eluting stent (DES) implantation using optical coherence tomography.
BACKGROUND NA is an important substrate for stent failure. In vivo NA characteristics in DM patients have not been
investigated.
METHODS A total of 397 patients with 452 DES who underwent follow-up optical coherence tomography examination
after DES implantation were enrolled. Characteristics of NA were compared between DM and non-DM patients. Neo-
vascularization was deﬁned as signal-poor holes or tubular structures with a diameter of 50 to 300 mm.
RESULTS A total of 123 DES with NA lesions in 115 patients were identiﬁed. The incidence of NA was similar between
DM and non-DM patients (29.6% vs. 28.6%; p ¼ 0.825). Compared with the non-DM group, neovascularization was
more frequently observed in the DM group (55.1% vs. 32.4%; p ¼ 0.012). The multivariate logistic model demonstrated
that DM (odds ratio: 3.00; 95% conﬁdence interval: 1.31 to 6.81; p ¼ 0.009) and follow-up duration (odds ratio:
1.03; 95% conﬁdence interval: 1.02 to 1.05; p < 0.001) were the independent predictors for neovascularization in
NA lesions. DM patients with glycated hemoglobin $7.0% had a higher prevalence of thin-cap ﬁbroatheroma compared
with those with glycated hemoglobin <7.0% (40.0% vs. 8.3%; p ¼ 0.01).
CONCLUSIONS The incidence of NA was similar between patients with and without DM. Neovascularization in
NA lesions was more frequent in those with DM. Poorly controlled DM patients had a higher incidence of thin-cap
ﬁbroatheroma, compared with those with well-controlled DM. (J Am Coll Cardiol Intv 2015;8:1044–52)
© 2015 by the American College of Cardiology Foundation.E merging evidence suggests in-stent neoather-osclerosis (NA) is an important substrate forboth in-stent restenosis and late stent throm-
bosis (1). Tian et al. (2) assessed the characteristics ofm the *Cardiology Division, Massachusetts General Hospital, Harvard M
rdiology, Asan Medical Center, University of Ulsan College of Medicine,
al, Yonsei University College of Medicine, Seoul, South Korea; xQueen
ivision of Cardiology, Kyung-Hee University, Seoul, South Korea; {The Fir
ra, Japan; #Biostatistics Center, Massachusetts General Hospital, Harva
epartment of Cardiology, 2nd Afﬁliated Hospital of Harbin Medical Univ
inese Ministry of Education, Harbin, China. Dr. Jang has received a resear
s received research grants from Boston Scientiﬁc and Medtronic. Dr. Verga
rdiology Award for Research Abroad. Dr. Yu has received a grant from
871064). All other authors have reported that they have no relationships
nuscript received December 3, 2014; revised manuscript received Januarneointimal hyperplasia after drug-eluting stent (DES)
implantation in patients with diabetes mellitus (DM)
by optical coherence tomography (OCT) and found
that glycated hemoglobin (A1C) levels in DM patientsedical School, Boston, Massachusetts; yDivision of
Seoul, South Korea; zSeverance Cardiovascular Hos-
Mary Hospital, Hong Kong University, Hong Kong;
st Department of Medicine, Nara Medical University,
rd Medical School, Boston, Massachusetts; and the
ersity, The Key Laboratory of Myocardial Ischemia,
ch grant and honorarium from St. Jude Medical; and
llo was funded in part by the 2013 Italian Society of
the National Natural Science Foundation of China
relevant to the contents of this paper to disclose.
y 21, 2015, accepted February 12, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
A1C = glycated hemoglobin
CKD = chronic kidney disease
DES = drug-eluting stent(s)
DM = diabetes mellitus
MGH = Massachusetts General
Hospital
NA = neoatherosclerosis
OCT = optical coherence
tomography
TCFA = thin-cap ﬁbroatheroma
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1045contributed to the development of neointimal hyper-
plasia and in-stent NA. However, the difference in NA
characteristics after DES implantation in patients
with and without DM has not been reported. OCT is
an emerging intravascular imaging modality with a
resolution of 10 to 20 mm. It can characterize micro-
scopic morphological features of atherosclerotic
plaques, such as ﬁbrous cap thickness, thin-cap
ﬁbroatheroma (TCFA), macrophage accumulations,
neovascularization, thrombus, and calciﬁcation (3).
The present study aimed to investigate characteris-
tics of NA in DM patients after DES implantation using
OCT imaging.
METHODS
STUDY POPULATION. The Massachusetts General
Hospital (MGH) OCT registry is a multicenter registry
of patients undergoing OCT of the coronary arteries
and includes 20 sites across 6 countries. Any patient
who underwent an OCT procedure was eligible for the
registry. For the present study, we identiﬁed 486
patients with 554 previously implanted DES from the
MGH OCT between August 2010 and November 2013.
Among these patients, we excluded those with <6
months of follow-up OCT examination (n ¼ 77). Stents
with poor OCT image quality (n ¼ 12) were also
excluded. A total of 452 DES in 397 patients were
included in the ﬁnal analysis. The presence of lipid-
laden neointima or calciﬁcation inside of the stents
was deﬁned as NA in the present study. Subjects were
assigned to the DM group if they were receiving an
oral hypoglycemic agent or insulin or if they had a
known fasting blood glucose value $126 mg/dl or
post-prandial 2-h blood glucose value $200 mg/dl.
NA characteristics were compared between DM
and non-DM subjects. Moreover, DM subjects were
divided into 2 groups based on A1C level <7.0%
or $7.0%, and NA characteristics were compared. The
study protocol was approved by the institutional re-
view board at each site, and written informed consent
was obtained from all patients. The MGH OCT Regis-
try is registered on ClinicalTrials.gov (NCT01110538).
QUANTITATIVE CORONARY ANGIOGRAPHY. Cor-
onary angiograms were analyzed using off-line
software (CAAS 5.10.1, Pie Medical Imaging BV,
Maastricht, the Netherlands). Diameter stenosis,
reference diameter, and minimum lumen diameter
were measured. Angiographic restenosis was de-
ﬁned as a diameter stenosis >50% at follow-up
angiography.
OCT IMAGE ACQUISITION. The time-domain OCT
system (M2/M3 Cardiology Imaging System, LightLabImaging, Inc., Westford, Massachusetts) or
the frequency-domain OCT system (C7-XR
OCT Intravascular Imaging System, St. Jude
Medical, St. Paul, Minnesota) was used in
this study. In the M2/M3 system, an occlu-
sion balloon (Helios, LightLab Imaging) was
inﬂated proximal to the stent at 0.4 to
0.6 atm during image acquisition. The opti-
cal probe was automatically pulled back from
distal to proximal at a rate of 1.0 to 3.0 mm/s,
and saline was continuously infused from the
tip of the occlusion balloon. In the C7XR
system, a 2.7-F OCT imaging catheter was
carefully advanced distal to the stent. The auto-
mated pullback was performed at 20 mm/s, while
blood was displaced by a short injection of contrast
media or Dextran through the guiding catheter (4).
All OCT images were stored digitally, deidentiﬁed,
and submitted to the MGH laboratory for off-line
analysis.
OCT IMAGE ANALYSIS. Cross-sectional OCT images
were analyzed at 1-mm intervals. For quantitative
analysis, stent and luminal cross-sectional areas
(CSAs) were measured, and neointimal hyperplasia
(NIH) CSA was calculated as: stent CSA  luminal CSA.
Mean values were reported in this study. The thick-
ness of neointimal hyperplasia was measured as the
distance between the endoluminal surface of the
neointima and the strut. An uncovered strut was
deﬁned when no material covering a strut was iden-
tiﬁed. The percentage of uncovered struts in each
stented lesion was calculated as: ([number of uncov-
ered struts/total number of struts in all cross sections
of the lesion]  100). For qualitative analysis, a lipid
was deﬁned as a diffusely bordered, signal-poor re-
gion with rapid signal attenuation. Lipid-laden neo-
intima was deﬁned as a neointima with lipid (5)
(Figure 1). Calciﬁcation was deﬁned as a clearly
delineated, signal-poor region with low backscatter.
TCFA was deﬁned by lipid-rich neointima with cap
thickness #65 mm and an angle of lipidic tissue $180
(6). Neovascularization was deﬁned as a signal-poor
hole or tubular structure with a diameter $50
and #300 mm that was present on at least 3 consec-
utive frames (7). Disrupted neointima was a break
in the ﬁbrous cap that connected the lumen with
the underlying lipid pool (8). Thrombus was a mass
protruding into the vessel lumen, discontinuous
from the surface of the vessel wall and with a
dimension $250 mm (9).
OCT images were analyzed at the MGH OCT core
laboratory by 2 independent investigators blinded to
patient information (L.G., T.S.). All cross-sectional
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1046images were initially screened for quality assessment
and were excluded from analysis if a side branch
occupied >45 of the cross section; if any portion of
the stent was out of the screen; or if the image had
poor quality caused by artifact, residual blood, or
reverberation. When there was discordance between
the readers, a consensus reading was obtained from a
third independent investigator (R.V.). Examples are
shown in Figure 1.
STATISTICAL ANALYSIS. Categorical data were
expressed as counts and percentages and compared
using a chi-square or Fisher exact test, depending on
the distribution of the data. Continuous measure-
ments were expressed as mean  SD and analyzed
with the Student t test. Multiple logistic regression
analyses were performed to assess the independent
predictors for the presence of neovascularization.FIGURE 1 Representative Images of Neoatherosclerosis
(A) Calciﬁed neointima is deﬁned as a signal-poor or heterogeneous regio
showing small vesicular or tubular structures with 50- to 300-mm diam
neointima shows a diffusely bordered signal-poor region with overlying
neointima. (D) Intimal rupture (red arrow) surrounded by thin-cap ﬁbro
struts.Multiple regression models included the parameters
that showed statistical signiﬁcance with p < 0.1 in
the univariate analysis. The Generalized Estimating
Equations approach was used to take into account the
within-subject correlation due to multiple stents
analyzed within a single patient. Interobserver and
intraobserver reliabilities were estimated using the k
coefﬁcient for the assessment of neointimal tissue
morphology. All statistical analyses were performed
with SPSS version 17.0 (SPSS Inc., Chicago, Illinois). A
2-tailed p value <0.05 was considered statistically
signiﬁcant.
RESULTS
CLINICAL CHARACTERISTICS. From a total of 397
patients, we identiﬁed 123 DES with NA lesions in 115
patients. There was no signiﬁcant difference in then with a sharply delineated border (red arrow). (B) Neovascularization
eter (red arrow) differentiated from branch vessels. Lipid-laden
signal-rich homogeneous band (white asterisks). (C) Lipid-laden
atheroma–containing neointima. All white arrowheads indicate stent
TABLE 1 Baseline Patient Characteristics
NA
(n ¼ 115)
Non-NA
(n ¼ 282) p Value
Age, yrs 61.3  12.6 61.1  9.8 0.829
Male 88 (76.5) 210 (74.5) 0.668
Hypertension 73 (63.5) 189 (67.0) 0.499
Hyperlipidemia 86 (74.8) 209 (74.1) 0.890
DM 45 (39.1) 107 (37.9) 0.825
Smoking 53 (46.1) 152 (53.9) 0.158
CAD family history 8 (7.0) 28 (9.9) 0.349
CKD 9 (7.8) 7 (2.5) 0.014
Creatinine, mg/dl 1.2  1.5 0.9  0.6 0.006
Total cholesterol, mg/dl 165.3  42.7 165.0  44.4 0.964
LDL cholesterol, mg/dl 93.8  32.2 90.1  34.7 0.315
Triglycerides, mg/dl 155.1  93.5 154.7  110.2 0.978
Fasting serum glucose, mg/dl 108.8  32.1 118.0  41.7 0.035
A1C, % 6.2  1.3 6.3  1.3 0.554
Prior myocardial infarction 23 (20.0) 79 (28.0) 0.097
Prior CABG 0 (0) 5 (1.8) 0.151
LVEF, % 61.5  8.5 62.6  8.3 0.237
Clinical presentation at stenting
ACS 39 (33.9) 116 (41.1) 0.181
SAP 76 (66.1) 166 (58.9) 0.181
Medications at follow-up
Statins 94 (81.7) 266 (94.3) <0.001
Aspirin 108 (93.9) 276 (97.9) 0.044
Clopidogrel 83 (72.2) 263 (93.3) <0.001
ACEI/ARB 56 (48.7) 118 (41.8) 0.212
b-blockers 62 (53.9) 144 (51.1) 0.606
Values are mean  SD or n (%).
A1C ¼ glycated hemoglobin; ACEI ¼ angiotensin-converting enzyme inhibitor; ACS ¼ acute coronary syndrome;
ARB ¼ angiotensin II receptor blocker; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease;
CKD ¼ chronic kidney disease; DM ¼ diabetes mellitus; LDL ¼ low-density lipoprotein; LVEF ¼ left ventricular
ejection fraction; NA ¼ neoatherosclerosis; SAP ¼ stable angina pectoris.
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1047incidence of NA (29.6% vs. 28.6%; p ¼ 0.825) be-
tween DM and non-DM patients. Patient character-
istics between the NA and non-NA groups are
summarized in Table 1. There was no signiﬁcant
difference in age, sex, prevalence of hypertension,
hyperlipidemia, smoking, and diabetes mellitus be-
tween the 2 groups. Creatinine level was signiﬁcantly
higher in NA patients than in non-NA patients (1.2 
1.5 mg/dl vs. 0.9  0.6 mg/dl; p ¼ 0.006). Chronic
kidney disease (CKD) (stages 3 to 5) was signiﬁcantly
more frequent in NA patients compared with non-NA
patients (7.8% vs. 2.5%; p ¼ 0.014). Although fasting
glucose level was lower in the NA group, A1c was not
different between the groups with and without NA.
The use of statins, aspirin, and clopidogrel was
signiﬁcantly less frequent in NA patients than in
non-NA patients.
The characteristics of 115 patients with NA by DM
status are summarized in Table 2. A total of 45 (39.1%)
patients had DM and 70 (60.9%) did not have DM.
No signiﬁcant differences were observed in the
baseline characteristics between the 2 groups, except
for a higher prevalence of CKD in the DM group (15.6%
vs. 2.9%; p ¼ 0.013). Medications at follow-up were
similar between the 2 groups, except for a lower
use of b-blockers in the DM group (40.0% vs. 65.7%;
p ¼ 0.007). The DM group consisted of 23 subjects
with A1C $7.0% and 22 subjects with A1C <7.0%. In the
A1C $7.0% group, 14 subjects (60.9%) were receiving
insulin therapy, 6 subjects (26.1%) were taking oral
agents, and 3 subjects (13.0%) were not taking any
medicine. In the A1C <7.0% group, 15 subjects (68.2%)
were receiving insulin therapy, 5 subjects (22.7%)
were taking oral agents, and 2 subjects (9.0%) were
not taking any medicine.
PROCEDURAL INFORMATION AND FOLLOW-UP
ANGIOGRAPHIC FINDINGS. Stent information and
the results of angiographic analysis between the DM
and non-DM groups are shown in Table 3. The
target vessel was the left anterior descending artery
in 50.4% of cases, the left circumﬂex in 17.1%, and
the right coronary artery in 31.7%. This distribution
was not different between the 2 groups. First-
generation DES was used in >75% of cases. Sub-
types of DES, stent diameter, and stent length were
not different between the 2 groups. As shown in
Table 3, in-stent percent diameter stenosis, mini-
mum lumen diameter, and incidence of in-stent
restenosis were not different between the DM and
non-DM groups.
OCT FINDINGS BETWEEN THE DM AND NON-DM
GROUPS. The mean follow-up duration betweenDES implantation and follow-up OCT study was
30.3  28.9 months in the DM group and 29.4  26.1
months in the non-DM group (p ¼ 0.856). All OCT
images at follow-up were acquired successfully
without any complications. Comparisons of quanti-
tative OCT ﬁndings between the DM and non-DM
groups are shown in Table 4. Mean luminal area,
stent area, and neointimal area were similar between
the 2 groups. The incidence of uncovered stent struts
was similar between the 2 groups. The prevalences of
OCT qualitative characteristics of NA are also shown
in Table 4. The prevalence of lipid-laden intima
was similar between the 2 groups, as was the preva-
lence of calciﬁcation, OCT-deﬁned TCFA, neointima
disruption, and thrombus. However, neovascul-
arization was observed more frequently in the DM
group (55.1% vs. 32.4%; p ¼ 0.012). Interobserver and
intraobserver agreements were k ¼ 0.92 and 0.94 for
lipid-laden intima and k ¼ 0.93 and 0.92 for neo-
vascularization, respectively.
TABLE 2 Baseline Patient Characteristics With NA
DM
(n ¼ 45)
Non-DM
(n ¼ 70) p Value
Age, yrs 60.5  12.3 61.9  12.9 0.562
Male 31 (68.9) 57 (81.4) 0.122
Hypertension 33 (73.3) 40 (57.1) 0.078
Hyperlipidemia 33 (73.3) 53 (75.7) 0.774
Smoking 18 (40.0) 35 (50.0) 0.294
CAD family history 1 (2.2) 7 (10.0) 0.110
CKD 7 (15.6) 2 (2.9) 0.013
Creatinine, mg/dl 1.5  1.7 1.1  1.3 0.147
Total cholesterol, mg/dl 167.3  47.3 164.0  39.9 0.684
LDL cholesterol, mg/dl 93.8  32.2 93.9  32.4 0.985
Triglycerides, mg/dl 165.0  112.3 148.7  79.3 0.365
Fasting serum glucose, mg/dl 129.5  39.6 95.5  15.7 <0.001
A1C, % 7.1  1.4 5.6  0.7 <0.001
Prior myocardial infarction 8 (17.8) 15 (21.4) 0.633
Prior CABG 0 (0) 0 (0) NS
LVEF, % 63.3  7.0 60.3  9.1 0.060
Clinical presentation at stenting
ACS 13 (28.9) 26 (37.1) 0.362
SAP 32 (71.1) 44 (62.9) 0.362
Medications at follow-up
Statins 37 (82.2) 57 (81.4) 0.914
Aspirin 43 (95.6) 65 (92.9) 0.555
Clopidogrel 33 (73.3) 50 (71.4) 0.824
ACEI/ARB 24 (53.3) 32 (45.7) 0.425
b-blockers 18 (40.0) 44 (65.7) 0.007
Values are mean  SD or n (%).
Abbreviations as in Table 1.
TABLE 3 Angiographic Characteristics
DM
(n ¼ 49)
Non-DM
(n ¼ 74) p Value
Location of stent
LAD 21 (42.9) 41 (55.4) 0.173
LCX 9 (18.4) 13 (17.6) 0.910
RCA 19 (38.8) 20 (27.0) 0.170
Stent diameter, mm 2.8  0.3 2.8  0.3 0.652
Stent length, mm 23.1  6.7 22.3  6.6 0.532
Stent type
SES 32 (65.3) 44 (59.5) 0.514
PES 6 (12.2) 12 (16.2) 0.542
ZES 4 (8.2) 4 (5.4) 0.544
EES 7 (14.3) 14 (18.9) 0.504
QCA at follow-up
Diameter stenosis, % 53.1  20.2 49.6  18.7 0.330
Minimum lumen diameter, mm 1.5  0.8 1.6  0.8 0.342
Reference diameter, mm 3.0  0.6 3.1  0.7 0.530
In-stent restenosis 28 (57.1) 43 (58.1) 0.916
Values are n (%) or mean  SD.
DM ¼ diabetes mellitus; EES ¼ everolimus-eluting stent(s); LAD ¼ left anterior
descending artery; LCX ¼ left circumﬂex artery; PES ¼ paclitaxel-eluting stent(s);
QCA ¼ quantitative coronary angiography; RCA ¼ right coronary artery;
SES ¼ sirolimus-eluting stent(s); ZES ¼ zotarolimus-eluting stent(s).
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1048MULTIPLE REGRESSION ANALYSES FOR NEO-
VASCULARIZATION FORMATION IN NA LESIONS.
As shown in Table 5, univariate and multivariate
logistic regression analysis were performed to assess
the determinants of neovascularization formation
in NA lesions. In the univariate model, DM, CKD,
follow-up duration, and statin use were all associated
with neovascularization formation in NA lesions. The
multiple logistic regression model demonstrated that
only DM and follow-up duration were independent
risk factors for neovascularization formation in NA
lesions after adjustment for other factors.
DM SUBGROUP ANALYSIS. DM patients were divided
into 2 subgroups depending on glycemic control: high
A1C group (A1C $7.0%, n ¼ 25) and the low A1C group
(A1C <7.0%, n ¼ 24) (Figure 2). The frequency of
OCT-deﬁned TCFA-containing neointima was signif-
icantly higher in the high A1C group than in the low
A1C group (40.0% vs. 8.3%; p ¼ 0.010). The preva-
lence of lipid-laden intima (100.0% vs. 100.0%),
calciﬁcation (12.0% vs. 4.2%; p ¼ 0.371), neo-
vascularization (48.0% vs. 62.5%; p ¼ 0.308), neo-
intima disruption (24.0% vs. 12.5%; p ¼ 0.299), and
thrombus (12.0% vs. 8.3%; p ¼ 0.672) were not
different between the 2 groups.
DISCUSSION
To the best of our knowledge, this is the ﬁrst study
utilizing OCT to compare NA characteristics between
patients with and without DM. The present study
demonstrated no signiﬁcant difference in the inci-
dence of NA between DM and non-DM patents after
2.5 years. Neovascularization was more frequent in
the DM group than in the non-DM group. When DM
patients were further divided into 2 groups based on
A1C level, the NA lesions in patients with A1C $7.0%
had a higher prevalence of OCT-deﬁned TCFA
compared with those with A1C <7.0%.
DM AND NA. The precise mechanisms of NA devel-
opment in DES remain unknown to date. Our previ-
ous study demonstrated that traditional clinical risk
factors for atherosclerosis in native coronary arteries
including DM were not associated with NA formation
(10). This is consistent with the present observations,
which showed no signiﬁcant difference in the preva-
lence of NA between DM and non-DM groups. This
may suggest a different mechanism in the develop-
ment of atherosclerosis inside the stents from those
in the native coronary arteries. Tian et al. (2) reported
that the prevalence of NA was 18.3% in DM patients
and 5.5% in non-DM patients. The prevalence of NA
was higher in our study compared with the report by
TABLE 4 OCT Findings in DM and Non-DM
DM
(n ¼ 49)
Non-DM
(n ¼ 74) p Value
Quantitative
Mean luminal area, mm2 5.8  1.6 6.1  1.5 0.192
Mean stent area, mm2 7.2  2.6 7.5  2.1 0.572
Mean neointimal area, mm2 1.4  0.6 1.5  0.8 0.424
Minimal luminal area, mm2 1.8  1.2 2.1  1.9 0.371
Neointimal thickness, mm 157  69 165  91 0.254
Uncovered stent strut, % 4.5  7.1 3.1  5.5 0.353
Qualitative
Lipid-laden intima 47 (95.9) 71 (94.7) 0.751
Calciﬁcation 4 (8.2) 6 (8.1) 0.991
Incidence of TCFA 12 (24.5) 25 (33.8) 0.271
Neovascularization 27 (55.1) 24 (32.4) 0.012
Disruption 9 (18.4) 16 (21.6) 0.661
Thrombus 5 (10.2) 17 (23.0) 0.070
Values are mean  SD or n (%).
DM ¼ diabetes mellitus; TCFA ¼ thin-cap ﬁbroatheroma.
TABLE 5 Multiple Logistic Regression Model for Neovascularization
Univariate Models Multivariate Models
Odds
Ratio 95% CI p Value
Odds
Ratio 95% CI p Value
Age, per yr 1.02 0.99–1.05 0.237
Male 0.82 0.36–1.86 0.629
First-generation DES 1.32 0.58–3.03 0.507
ACS 1.43 0.69–2.96 0.337
DM 2.56 1.21–5.38 0.013 2.57 1.09–6.07 0.031
Hypertension 1.34 0.72–2.11 0.352
Hyperlipidemia 0.74 0.33–1.67 0.471
CKD 4.28 1.08–17.02 0.039 2.87 0.63–13.02 0.171
Follow-up duration,
months
1.03 1.02–1.05 <0.001 1.03 1.02–1.05 <0.001
Stent diameter, per mm 0.66 0.15–2.84 0.576
Stent length, per mm 1.02 0.96–1.07 0.572
ACEI/ARB use 1.74 0.85–3.60 0.133
Statin use 0.42 0.16–1.07 0.069 0.65 0.22–1.92 0.435
CI ¼ conﬁdence interval; DES ¼ drug-eluting stent(s); other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5 Gao et al.
J U L Y 2 0 1 5 : 1 0 4 4 – 5 2 Neoatherosclerosis and Diabetes Mellitus
1049Tian et al. (2). The most likely explanation for this
discrepancy is that mean follow-up time was almost
30 months in our study, whereas the study by Tian
et al. (2) included patients with OCT follow-up only 12
months after DES implantation. Previous OCT studies
demonstrated more frequent lipid-laden neointima in
late restenosis of bare-metal stents compared with
early restenosis (11,12). Also in DES, Kang et al. (13)
demonstrated that the incidence of TCFA increases
over time and that the best cutoff of follow-up time to
predict TCFA was 20 months. Irrespective of stent
type, stent age is obviously 1 of the strongest pro-
moting factors for NA (10).
NA CHARACTERISTICS IN DM AND NON-DM PATIENTS.
Diabetes is an independent factor for mortality in
coronary artery disease, especially in acute coronary
syndrome, which may be due to metabolic abnor-
malities and atherosclerotic plaque characteristics in
DM patients. A post-mortem study showed that,
compared with non-DM patients, DM patients had
plaques with larger necrotic cores and increased
macrophage inﬁltration (14). A recent in vivo study
demonstrated that nonculprit plaques in patients
with DM had a wider lipid arc, a longer lipid length, a
larger lipid index, and a higher prevalence of calciﬁ-
cation and thrombus (15). However, few studies have
explored the NA morphology in diabetic patients.
The present study demonstrated that NA character-
istics, including the presence of lipid-laden intima,
calciﬁcation, TCFA-containing neointima, neointima
disruption, and thrombus detected by OCT, were not
different between DM and non-DM patients; howev-
er, neovascularization formation was more frequently
observed in the DM group. Recently, Suzuki et al.
(16) reported a similar observation that microvessels
were observed frequently in in-stent restenotic
tissue in patients with DM.
Neovascularization has been recognized as an
important process for the progression of atheroscle-
rotic plaques and has also been recently identiﬁed as
1 of the features of plaque vulnerability (17,18).
The molecular mechanisms underlying plaque neo-
vascularization are not fully understood. DM is asso-
ciated with pro-oxidative and inﬂammatory states
leading to systemic elevation of endothelial adhesion
molecules and cytokines, which leads to increased
leucocyte emigration, monocyte/macrophage inﬂux,
and subintimal proliferation favoring neovessel for-
mation. Recent studies have documented increased
inﬂammation, neovascularization, and intraplaque
hemorrhage in human diabetic atherosclerosis (19,20).
Previous investigations using OCT showed that neo-
vascularization might play a key role in identifyinglesions more prone to plaque destabilization and
rupture (21). Inhibition of neovascularization is an
effective approach to treat and prevent de novo
atherosclerosis (22). Following stent implantation,
the expression of lipid-laden intima is closely associ-
ated with neointimal neovascularization (11). Tian
et al. (23) also observed that the incidence of NA was
higher in the sections with a higher degree of neo-
vascularization. These results indicate that expanded
neointima neovascularization may also play a key role
in NA progression and tissue instability. According to
our results, neovascularization was more frequently
observed in NA areas in patients with DM. Thus, it is
conceivable that inhibition of neovascularization may
FIGURE 2 Comparison of Neoatherosclerosis Characteristics Between High A1C Group
and Low A1C Group
A1C ¼ glycated hemoglobin; TCFA ¼ thin-cap ﬁbroatheroma.
Gao et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5
Neoatherosclerosis and Diabetes Mellitus J U L Y 2 0 1 5 : 1 0 4 4 – 5 2
1050be an effective approach for preventing NA in DM
patients.
NA CHARACTERISTICS IN THE POORLY CONTROLLED
DM GROUP (A1C ‡7.0%). Our previous study suggested
that patients with poorly controlled DM had more
vulnerable plaques in the native nonculprit coronary
lesions (15). However, the association of A1C level with
the characteristics of NA has not been investigated.
The present study showed that the frequency of OCT-
deﬁned TCFA-containing neointima was signiﬁcantly
higher in the high A1C group than in the low A1C group
(40.0% vs. 8.3%; p ¼ 0.010). It coincides with the
typical pathological features of vulnerable plaque in
native coronary arteries (24). In the contemporary DES
era, prospective studies have shown that A1C level is 1
of the most important risk factors for adverse clinical
events in DM patients (25,26). A recent study reported
that the adjusted risk of major adverse cardiovascular
events in diabetic patients with poor glycemic control
(A1C $7.0%) was more than double the risk in non-
diabetics. This same study also showed that well-
controlled diabetic patients had rates of adverse
clinical events comparable to those of nondiabetic
patients (27). Previous studies demonstrated that
TCFA-containing neointima might lead to neointimal
rupture and stent thrombosis (28). Furthermore,
Thrombolysis In Myocardial Infarction ﬂow at pre-
sentation was reduced in lesions showing neointimalrupture or TCFA-containing neointima (13), and pre-
procedural OCT ﬁndings of TCFA-containing neo-
intima were signiﬁcantly correlated with the peak
level of post-percutaneous coronary intervention
creatine kinase-myocardial band (29). The current
ﬁndings suggest that 1 possible explanation for higher
rates of major adverse cardiac events may be the
presence of more vulnerable morphology features in
diabetic patients with worse glycemic control.
Signal attenuation due to lipid-laden neointima
and calciﬁcation and limited penetration depth of
OCT images may not allow accurate evaluation of
neovascularization in deep layers. In the present
study, we found that although neovascularization
was more commonly observed in patients with DM,
there was similar incidence of neovascularization in
subjects with HbA1c <7.0% compared with those with
HbA1c $7.0%. One possible explanation is that the
higher incidence of TCFA and calciﬁcation in the
HbA1c $7.0% group (Figure 2) may have caused un-
derestimation of the incidence of neovascularization
in the group.
STUDY LIMITATIONS. First, this is a retrospective
study using a registry database. Therefore, potential
selection bias is unavoidable. Given the international
multisite nature of the registry, we explored potential
between-country differences in the prevalence of DM
and neoatherosclerosis in our study population and
found no statistically signiﬁcant differences (data not
shown). Second, this is not a natural history study of
stented lesions in which the same stents are serially
studied at different time points after implantation.
Third, 4 types of DES, including sirolimus-, pacli-
taxel-, zotarolimus-, and everolimus-eluting stents,
were included in the present study. Because of the
relatively small number of each DES subtype, we
could not evaluate the difference in the nature of NA
among the subtypes of DES. Finally, lipid-laden in-
tima, calciﬁcation, OCT-deﬁned TCFA-containing
neointima, neovascularization, neointimal disrup-
tion, and thrombus were not quantiﬁed or rigorously
validated. Nakano et al. (30) reported that foamy
macrophages accumulate on the luminal surface of
neointimal in the stented coronary artery, which are
identiﬁed in OCT as a typical appearance of a thin
bright line with trailing shadows. This feature might
have led to an overestimation of the presence of
TCFA-containing neointima (30).
CONCLUSIONS
The present study provides several unique and
potentially important insights into NA characteristics
PERSPECTIVES
WHAT IS KNOWN? Previous studies have reported that in-stent
NA is an important mechanism for both in-stent restenosis and late
stent thrombosis. However, the difference in NA characteristics after
DES implantation in patients with and without DM has not been
explored.
WHAT IS NEW? The present study demonstrated that NA lesions
in DM patients had a higher prevalence of neovascularization.
Moreover, patients with poorly controlled DMhad lesionswithmore
vulnerable features.
WHAT IS NEXT? Prospective studies are needed to test if
better control of DM will prevent late stent complications
related to NA.
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1051after coronary DES implantation in DM patients
versus non-DM patients. Although the incidence of
NA was similar between DM and non-DM patients, NA
lesions in DM patients had a higher prevalence of
neovascularization. Moreover, patients with poorly
controlled DM had lesions containing more vulner-
able features. Further studies are warranted to aid in
understanding the clinical implication of the present
ﬁndings and whether vulnerable features of NA
are associated with higher event rates in poorly
controlled diabetic patients.
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